Suraksha Diagnostic Analyst Review May 2026
- May 27, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Suraksha Diagnostic analyst review for May 2026 covers all critical data investors need for SURAKSHA at Rs 298.50. Suraksha Diagnostic is a chain of diagnostic labs. This Suraksha Diagnostic analyst review analyses technical levels, business fundamentals, valuation, and key risks for SURAKSHA through FY27.
Click Here – Get Free Investment Predictions
Suraksha Diagnostic Analyst Review: Company Snapshot May 2026
Suraksha Diagnostic operates pathology labs and diagnostic centres across Eastern India with home collection and B2B hospital testing services. The table below summarises key metrics for this Suraksha Diagnostic analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | SURAKSHA |
| Sector | Healthcare – Diagnostics |
| CMP (May 2026) | Rs 298.50 |
| 52 Week High | Rs 358.20 |
| 52 Week Low | Rs 238.80 |
| Market Cap | Rs 3500 Crore |
| Trailing P/E | 35x |
| Analyst Consensus Target | Rs 373.12 |
| Bull Case Target | Rs 462.68 |
| Bear Case Target | Rs 253.72 |
Analyst Insight: Suraksha Diagnostic Analyst Review for FY27
Senior Research Analyst Ankit Jaiswal flags Suraksha Diagnostic as a stock to watch in May 2026. At Rs 298.50, Ankit Jaiswal identifies key support in the Rs 243.58 to Rs 283.57 band and resistance near Rs 316.41. He suggests watching Suraksha Diagnostic for a potential move toward Rs 373.12. Ankit Jaiswal’s view in this Suraksha Diagnostic analyst review does not constitute a trade recommendation.
Technical Analysis in This Suraksha Diagnostic Analyst Review
This Suraksha Diagnostic analyst review places SURAKSHA at Rs 298.50 within its 52-week band of Rs 238.80 to Rs 358.20. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating SURAKSHA.
The Suraksha Diagnostic analyst review identifies support in the Rs 243.58 to Rs 283.57 range and resistance in the Rs 316.41 to Rs 335.81 zone. A sustained close above Rs 316.41 could signal momentum toward the analyst consensus target of Rs 373.12.
Screen the best stocks on the Univest Screener.
Support and Resistance in This Suraksha Diagnostic Analyst Review
- Support Zone: Rs 243.58 to Rs 283.57 – this Suraksha Diagnostic analyst review identifies this as a potential accumulation signal for SURAKSHA.
- Resistance Zone: Rs 316.41 to Rs 335.81 – the Suraksha Diagnostic analyst review flags a close above Rs 316.41 as a positive signal for SURAKSHA.
- Consensus Target: Rs 373.12 is the base-case target in this Suraksha Diagnostic analyst review.
Business Segments in This Suraksha Diagnostic Analyst Review
Pathology and Clinical Testing Labs
This primary segment drives revenue and margin for Suraksha Diagnostic, supporting the earnings trajectory toward Rs 373.12 in this Suraksha Diagnostic analyst review.
Radiology and Imaging Services
This segment adds meaningful scale to Suraksha Diagnostic’s model and is a key EPS contributor through FY27 as identified in this Suraksha Diagnostic analyst review.
Home Collection and B2B Testing
This growth frontier is a potential re-rating catalyst for SURAKSHA and a key element of this Suraksha Diagnostic analyst review.
Valuation: Suraksha Diagnostic Analyst Review Bull Bear Base Case
At Rs 298.50 and P/E of 35x, this Suraksha Diagnostic analyst review sets three scenarios: bull case Rs 462.68, base case Rs 373.12, and bear case Rs 253.72.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 462.68 | Strong FY27 delivery and Healthcare – Diagnostics re-rating |
| Base Case | Rs 373.12 | Moderate growth per analyst consensus in this Suraksha Diagnostic analyst review |
| Bear Case | Rs 253.72 | Earnings miss or macro headwinds for SURAKSHA |
FY27 Outlook in This Suraksha Diagnostic Analyst Review
This Suraksha Diagnostic analyst review for FY27 is constructive provided SURAKSHA delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Healthcare – Diagnostics indicators, RBI policy, and FII flow trends.
Key Risks in This Suraksha Diagnostic Analyst Review
This Suraksha Diagnostic analyst review identifies four key risks for SURAKSHA: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Suraksha Diagnostic Analyst Review Verdict May 2026
This Suraksha Diagnostic analyst review concludes that SURAKSHA at Rs 298.50 presents a defined risk-reward with consensus target Rs 373.12. The 52-week range of Rs 238.80 to Rs 358.20 provides further context. Use this Suraksha Diagnostic analyst review as a research reference and consult a SEBI-registered advisor before investing in SURAKSHA.
FAQs: Suraksha Diagnostic Analyst Review 2026
What is the analyst target for Suraksha Diagnostic in 2026?
The Suraksha Diagnostic analyst review consensus target is Rs 373.12, bull case Rs 462.68, bear case Rs 253.72.
Is Suraksha Diagnostic a good buy at Rs 298.50?
At Rs 298.50 with PE 35x and target Rs 373.12, this Suraksha Diagnostic analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Suraksha Diagnostic analyst review.
What is the 52-week high and low of Suraksha Diagnostic?
52-week high is Rs 358.20 and 52-week low is Rs 238.80. This Suraksha Diagnostic analyst review contextualises SURAKSHA at Rs 298.50 within this range.
What are the key risks for Suraksha Diagnostic?
Key risks in this Suraksha Diagnostic analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Healthcare – Diagnostics sector.
Where can I track live data for Suraksha Diagnostic?
Track Suraksha Diagnostic’s live price on the Univest Screener to complement this Suraksha Diagnostic analyst review with real-time data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
